'Pharma clinical trial services market will reach $30.6 billion in 2015' Predicts Visiongain

A new report by Visiongain predicts that the world market for pharma clinical trial services will be worth $30.6bn in 2015. Between 2011 and 2017, the global market will grow with a high single digit CAGR.
Pharma Clinical Trial Services World Market 2013-2
Pharma Clinical Trial Services World Market 2013-2
Spread the Word
Listed Under

* Clinical Trial
* Pharma Pipelines
* Drug developer
* E-clinical Tool

* Biotech
* Medical

* London City - London, Greater - England

* Reports

Jan. 31, 2013 - PRLog -- A new report by Visiongain predicts that the world market for pharma clinical trial services will be worth $30.6bn in 2015. Between 2011 and 2017, the global market will grow with a high single digit CAGR. Demand for late phase trial services will drive growth to 2023. Those findings appear in Pharma Clinical Trial Services: World Market 2013-2023, published in January 2013.

Throughout the 10-year forecast period, late-stage trials will account for the greatest proportion of revenues for clinical research organisations (CROs). In the first half of the forecast period, lifecycle management strategies, demands from regulators for post-marketing safety studies and pharma co economic data will drive growth in that industry.

Richard Lang, a pharmaceutical industry analyst for visiongain, said: “In the last decade, demand for outsourced clinical trial services grew rapidly as pharma pipelines grew and trials became increasingly large and complex. Drug developers built up large, complex networks of service providers, which they are now seeking to simplify. They are looking to form strategic partnerships with a select few CROs covering long-term development projects.

“CROs must expand to offer a one-stop shop for pharmaceutical clients in order to take advantage of these strategic partnerships. They will look to new technology, including e-clinical tools, to improve their service offerings, as well as expanding into emerging markets. Many leading CROs established bases in BRIC nations in the last decade. In this decade, growth for these CROs will be focused on building upon the service portfolio in these markets, as well as entering new emerging markets in Asia, Latin America and Central and Eastern Europe.”

Opportunities for growth in this decade for small CROs will stem from specialisation. Demand for biomarker validation services offers one potential niche area in which all larger CROs have yet to invest heavily. Therapeutic specialisation offers another opportunity to these companies. Cancer, cardiovascular diseases and CNS disorders accounted for more than half of clinical trial service revenues in 2011. Strong growth is expected in all three sectors of the market in this decade, driven by rising disease incidence and unmet treatment needs. There were close to 1,000 cancer drugs in clinical development in 2012, with many more in pre-clinical development.

The new study forecasts the leading national pharma clinical trials service markets. In 2011, the US and Western Europe dominated the market, accounting for more than three quarters of global revenues. During this decade, however, pharmaceutical clients will increasingly demand trial services in emerging countries. Lower costs and large treatment-naïve patient populations will drive this demand, as will access to rapidly emerging pharmaceutical markets. The market share for the BRIC nations (Brazil, Russia, India and China) will triple during the period 2011-2023. The US will continue to be the largest market for clinical trial services throughout the decade however.

Pharma Clinical Trial Services: World Market 2013-2023 provides quantitative and qualitative analysis of the clinical trial services market. It shows revenue forecasts for world-level submarkets and national markets. Also, it identifies future trends that will affect market players. The study adds to Visiongain’s portfolio of analytical reports covering the pharmaceutical outsourcing and service markets.

For further information concerning the Visiongain’s Pharma Clinical Trial Services: World Market 2013-2023 report please visit: http://www.visiongain.com/Report/973/Pharma-Clinical-Tria...

Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100
Companies Listed  3C Alliance
Agência Nacional de Vigilância Sanitária (ANVISA) [Brazil]
Agility Clinical
ASAN Medical Center
Associação Brasileira de CROs (Abracro)
Association for the Accreditation of Human Research Protection Programs (AAHRPP)
Association of Clinical Trial Organisations (ACTO) [Russia]
Astellas Pharma
Avista Capital Partners
BeijingWits Medical Consulting (part of ICON)
Berry Consultants
BioDuro (part of PPD)
BioDuro Biologics
Boehringer Ingelheim
Bristol-Myers Squibb
Caprion Proteomics
Center for Biologics Evaluation and Research (CBER) [US]
Central Drugs Standard Control Organization (CDSCO) [India]
Charles River Laboratories
Chinese Ministry of Commerce
Clinical Trial Support
Clinigene International
Clinipace Worldwide
CMIC (Beijing) Co
CNS Healthcare
CNS Vital Signs
Cogtest (part of The Cognition Group)
Corex Pharmaceutical
Council for International Organizations of Medical Sciences (CIOMS)
Cromos Pharma
Czura Thornton
Dako (part of Agilent Technologies)
Department of Health [UK]
Drug Controller General of India (DCGI)
Ekam Imaging
Eli Lilly
European Commission
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Medicines Agency (EMA)
European Parliament
Firecrest Clinical (part of ICON)
Food and Drug Administration (US FDA)
GCP ClinPlus
GE Healthcare
Genstar Capital
Global CNS Research
Global Research Services (GRS)
Hellman & Friedman
i3 Research (part of inVentiv Health)
INC Research
Infociencia (part of RPS)
Innovative Medicines Initiative (IMI)
Institute for Medical Research Management and Biometrics (IMEREM, part of RPS)
International Cancer Genome Consortium
International Conference of Harmonisation (ICH)
inVentiv Health
Japan Pharmaceutical Manufacturers Association (JPMA)
Java Clinical
Kendle (part of INC Research)
Kforce Clinical Research (KCR, part of inVentiv Health)
Kinship Technologies (part of PRA)
Korea Drug Development Fund (KDDF)
Korea Food and Drug Administration (KFDA)
Korea National Enterprise for Clinical Trials (KoNECT)
Kun Tuo (part of Quintiles)
LSK Global
MAB Discovery
Malaysian Biotechnology Corporation
Maximax Pharmaceutical Research
MDS Pharma Services (part of INC Research)
Medicines and Healthcare products Regulatory Agency (MHRA) [UK]
Medidata Solutions
Medipal Holdings
Merck & Co.
Merck KGaA
Ministry of Health, Labor and Welfare (MHLW, Japan)
Molecular Neuroimaging
Myriad Genetics
National Cancer Institute (NCI) [US]
National Taiwan University Hospital (NTUH)
Nautic Partners
NextGen Sciences
Nexus Oncology
NHS Research Scotland (NRS)
Ontario Teachers' Pension Plan
Oxford Cancer Biomarkers
Oxford Gene Technology (OGT)
Oxford Outcomes (part of ICON)
Pacific Biomarkers
Paragon Biomedical (part of Clinipace Worldwide)
Paramax International (part of RPS)
Parexel International
Perceptive Informatics (part of Parexel)
PFC Pharma Focus (part of Clinipace Worldwide)
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
PharmaNet Development Group (part of inVentiv Health)
PRA International
Prana Biotechnology
PriceSpective (part of ICON)
Prodia Clinical Laboratory
Proteome Sciences
ProTrials Research
Psychmed (part of The Cognition Group)
QED Clinical Services
Regulus Pharmaceutical Consulting (part of Clinipace Worldwide)
ReSearch Pharmaceutical Services (RPS)
Rules Based Medicine (now Myriad RBM, part of Myriad Genetics)
Email:***@visiongain.com Email Verified
Zip:EC1V 2QY
Tags:Clinical Trial, Pharma Pipelines, Drug developer, E-clinical Tool
Industry:Biotech, Medical
Location:London City - London, Greater - England
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Visiongain News
Daily News
Weekly News

Like PRLog?
Click to Share